Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 2.5% - Time to Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) rose 2.5% during mid-day trading on Monday . The company traded as high as $0.34 and last traded at $0.32. Approximately 48,039,653 shares changed hands during trading, a decline of 32% from the average daily volume of 70,497,063 shares. The stock had previously closed at $0.31.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a report on Wednesday, January 1st. They issued a "hold" rating for the company.

Tonix Pharmaceuticals Stock Performance

The company has a market capitalization of $58.40 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. The firm has a fifty day simple moving average of $0.24 and a 200 day simple moving average of $0.34. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analysts' expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.